FDA approves new cardiovascular drug based on study from Canadian VIGOUR Centre
The U.S. Food and Drug Administration has approved the drug vericiguat for use in patients with heart failure. The drug–a first-of-its-kind, once-daily oral treatment for patients with worsening chronic heart failure–was approved in part thanks to the VICTORIA (Vericiguat Global Study In Subjects With Heart Failure With Reduced Ejection Fraction) clinical study run by researchers…